Asundexian versus Apixaban in Patients with Atrial Fibrillation - PubMed Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment...

9) Another small molecule, #asundexian, was being studied vs #apixaban for #SPAF in #OCEANIC_AF, but that trial was prematurely terminated due to inferior efficacy of the #FXIa inhibitor. See pubmed.ncbi.nlm.nih.gov/39225267/ & discussion by @CMichaelGibson at cardiometabolic-ce.com/antithrombot....